ES2633468T3 - Agente inductor de inmunidad y método para la detección del cáncer - Google Patents
Agente inductor de inmunidad y método para la detección del cáncer Download PDFInfo
- Publication number
- ES2633468T3 ES2633468T3 ES09794513.3T ES09794513T ES2633468T3 ES 2633468 T3 ES2633468 T3 ES 2633468T3 ES 09794513 T ES09794513 T ES 09794513T ES 2633468 T3 ES2633468 T3 ES 2633468T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- polypeptide
- amino acid
- inducing agent
- cancer detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Agente para su uso en un método para la terapia y/o la profilaxis del cáncer de mama y/o la leucemia, en donde dicho agente comprende como principio activo al menos un polipéptido seleccionado entre los polipéptidos (a) a (c) a continuación, teniendo dicho polipéptido una(s) actividad(es) inductora(s) de la inmunidad o como principio(s) activo(s) un/unos vectore(s) recombinante(s) que comprende(n) un/unos polinucleótido(s) que codifica(n) dicho(s) polipéptido(s) y que es/son capaz/capaces de expresar dicho(s) polipéptido(s) in vivo: (a) un polipéptido que consiste en una cualquiera de las secuencias de aminoácidos mostradas en las ID con número impar de las SEQ ID NO: 3 a 95; (b) un polipéptido que consiste en la secuencia de aminoácidos mostrada en la SEQ ID NO: 108, la SEQ ID NO: 109, la SEQ ID NO: 110, la SEQ ID NO: 111, la SEQ ID NO: 112, la SEQ ID NO: 113, la SEQ ID NO: 114, la SEQ ID NO: 115, la SEQ ID NO: 116 o la SEQ ID NO: 117; y c) un polipéptido que comprende una secuencia parcial del mismo con una secuencia de aminoácidos como se muestra en la SEQ ID NO: 108, la SEQ ID NO: 109, la SEQ ID NO: 110, la SEQ ID NO: 111, la SEQ ID NO: 112, la SEQ ID NO: 113, la SEQ ID NO: 114, la SEQ ID NO: 115, la SEQ ID NO: 116 o la SEQ ID NO: 117, teniendo dicho polipéptido de 8 a 12 restos de aminoácidos.
Description
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008180548 | 2008-07-10 | ||
| JP2008180548 | 2008-07-10 | ||
| PCT/JP2009/062574 WO2010005069A1 (ja) | 2008-07-10 | 2009-07-10 | 免疫誘導剤及び癌の検出方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2633468T3 true ES2633468T3 (es) | 2017-09-21 |
Family
ID=41507179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09794513.3T Active ES2633468T3 (es) | 2008-07-10 | 2009-07-10 | Agente inductor de inmunidad y método para la detección del cáncer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8901082B2 (es) |
| EP (1) | EP2319533B1 (es) |
| JP (1) | JP5703562B2 (es) |
| KR (1) | KR101323192B1 (es) |
| CN (1) | CN102089001B (es) |
| AU (1) | AU2009270182B2 (es) |
| BR (1) | BRPI0910513B8 (es) |
| CA (1) | CA2730088C (es) |
| DK (1) | DK2319533T3 (es) |
| ES (1) | ES2633468T3 (es) |
| HU (1) | HUE035804T2 (es) |
| MX (1) | MX2011000116A (es) |
| PL (1) | PL2319533T3 (es) |
| PT (1) | PT2319533T (es) |
| RU (1) | RU2519675C2 (es) |
| WO (1) | WO2010005069A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2305300T3 (pl) | 2008-07-10 | 2016-09-30 | Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi | |
| WO2012074642A1 (en) | 2010-10-28 | 2012-06-07 | Shaw Industries Group, Inc. | Methods and devices for controlling a tufting machine for forming tufted carpet |
| GB201520565D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| CN108601822B (zh) | 2016-03-28 | 2022-07-22 | 东丽株式会社 | 免疫诱导剂 |
| JP7796376B2 (ja) * | 2021-03-31 | 2026-01-09 | 学校法人藤田学園 | 牛乳アレルギーの新規抗原 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU640397B2 (en) | 1989-08-25 | 1993-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6703360B2 (en) * | 2000-04-07 | 2004-03-09 | Heska Corporation | Compositions and methods related to canine IgG and canine IL-13 receptors |
| RU2311920C2 (ru) * | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
| CA2469833C (en) * | 2001-12-21 | 2008-05-20 | Idexx Laboratories, Inc. | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| US20040110933A1 (en) * | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
| AU2003298786A1 (en) * | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| JPWO2005083074A1 (ja) | 2004-03-01 | 2007-11-22 | 有限会社金沢大学ティ・エル・オー | 腫瘍抗原ペプチド |
| JP4547197B2 (ja) * | 2004-06-30 | 2010-09-22 | 公正 安元 | 癌特異的腫瘍抗原 |
| WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
| US20100233167A1 (en) * | 2007-05-10 | 2010-09-16 | Ramesh Bhatt | Chain reaction creating oligomers from repeat units of binding molecules |
-
2009
- 2009-07-10 PT PT97945133T patent/PT2319533T/pt unknown
- 2009-07-10 AU AU2009270182A patent/AU2009270182B2/en active Active
- 2009-07-10 RU RU2011104704/15A patent/RU2519675C2/ru active
- 2009-07-10 BR BRPI0910513A patent/BRPI0910513B8/pt active IP Right Grant
- 2009-07-10 EP EP09794513.3A patent/EP2319533B1/en active Active
- 2009-07-10 KR KR1020107029901A patent/KR101323192B1/ko active Active
- 2009-07-10 CN CN200980126587.8A patent/CN102089001B/zh active Active
- 2009-07-10 CA CA2730088A patent/CA2730088C/en active Active
- 2009-07-10 WO PCT/JP2009/062574 patent/WO2010005069A1/ja not_active Ceased
- 2009-07-10 ES ES09794513.3T patent/ES2633468T3/es active Active
- 2009-07-10 MX MX2011000116A patent/MX2011000116A/es active IP Right Grant
- 2009-07-10 DK DK09794513.3T patent/DK2319533T3/en active
- 2009-07-10 JP JP2009530725A patent/JP5703562B2/ja active Active
- 2009-07-10 US US13/002,629 patent/US8901082B2/en active Active
- 2009-07-10 HU HUE09794513A patent/HUE035804T2/en unknown
- 2009-07-10 PL PL09794513T patent/PL2319533T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2319533T3 (en) | 2017-07-17 |
| EP2319533B1 (en) | 2017-05-10 |
| JP5703562B2 (ja) | 2015-04-22 |
| PL2319533T3 (pl) | 2017-10-31 |
| RU2519675C2 (ru) | 2014-06-20 |
| BRPI0910513B1 (pt) | 2020-06-16 |
| KR20110019766A (ko) | 2011-02-28 |
| CA2730088C (en) | 2020-04-14 |
| CA2730088A1 (en) | 2010-01-14 |
| BRPI0910513B8 (pt) | 2021-05-25 |
| CN102089001B (zh) | 2015-01-14 |
| WO2010005069A1 (ja) | 2010-01-14 |
| AU2009270182B2 (en) | 2015-01-22 |
| EP2319533A1 (en) | 2011-05-11 |
| KR101323192B1 (ko) | 2013-10-30 |
| PT2319533T (pt) | 2017-07-20 |
| MX2011000116A (es) | 2011-02-25 |
| US20110130343A1 (en) | 2011-06-02 |
| BRPI0910513A2 (pt) | 2015-09-29 |
| HUE035804T2 (en) | 2018-05-28 |
| JPWO2010005069A1 (ja) | 2012-01-05 |
| RU2011104704A (ru) | 2012-08-20 |
| US8901082B2 (en) | 2014-12-02 |
| AU2009270182A1 (en) | 2010-01-14 |
| CN102089001A (zh) | 2011-06-08 |
| EP2319533A4 (en) | 2012-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2619322T3 (es) | Agente inductor de inmunidad | |
| MX2020013624A (es) | Agonistas del receptor glp-1 y usos de los mismos. | |
| ES2638278T3 (es) | Antagonistas de wnt y métodos de tratamiento | |
| ES2540858T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención de cáncer | |
| CO6210757A2 (es) | Proeina de fusion que comprende prame o un fragmento inmunogenico del mismo | |
| AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
| MX2024015050A (es) | L-asparaginasa modificada | |
| ES2565060T3 (es) | Polipéptidos que tienen actividad de glucoamilasa y polinucleótidos que codifican los mismos | |
| MX387259B (es) | Agonistas receptores de glp-1 y usos de los mismos | |
| NZ749962A (en) | Pegylated porcine interferon and methods of use thereof | |
| AR105592A1 (es) | b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS | |
| PE20191203A1 (es) | Variantes de alfa-glucosidasa acida y usos de las mismas | |
| MX380971B (es) | Cabezal para un implemento para el cuidado bucal. | |
| AR073170A1 (es) | Vacunas de poliproteinas recombinantes para el tratamiento y diagnostico de leishmaniasis | |
| MX2017004211A (es) | Reglas para modos de prediccion intra-imagen cuando se habilita el procesamiento paralelo de onda frontal. | |
| AR086998A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| MX377804B (es) | Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc). | |
| ES2666397T3 (es) | Activación de CD89 en terapia | |
| ES2722799T3 (es) | Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13 | |
| ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
| AR087091A1 (es) | Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso | |
| MX2017007127A (es) | Composiciones que comprenden polipeptidos que tienen actividad xilanasa y polipeptidos que tienen actividad arabinofuranosidasa. | |
| MX2020011007A (es) | Derivado de péptido-1 (glp-1) similar al glucagón acilado. | |
| BR112016017997A2 (pt) | Beta aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos | |
| AR055179A1 (es) | Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas |